• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

One stone, two birds: Improvement of early-onset vitiligo under apremilast in a patient with plaque psoriasis.

作者信息

Plachouri Kerasia-Maria, Kyriakou Georgia, Chourdakis Vlassios, Georgiou Sophia, Grafanaki Katerina

机构信息

Department of Dermatology, University of Patras, University General Hospital of Patras, Rio, Greece.

出版信息

Dermatol Ther. 2019 Sep;32(5):e13064. doi: 10.1111/dth.13064. Epub 2019 Sep 5.

DOI:10.1111/dth.13064
PMID:31414705
Abstract
摘要

相似文献

1
One stone, two birds: Improvement of early-onset vitiligo under apremilast in a patient with plaque psoriasis.一石二鸟：阿普司特治疗斑块状银屑病患者时早期白癜风病情改善
Dermatol Ther. 2019 Sep;32(5):e13064. doi: 10.1111/dth.13064. Epub 2019 Sep 5.
2
Combination therapy of apremilast and secukinumab in patients with moderate-to-severe, recalcitrant plaque psoriasis.阿普米拉斯与司库奇尤单抗联合治疗中重度、顽固性斑块状银屑病患者。
Clin Exp Dermatol. 2019 Oct;44(7):e243-e244. doi: 10.1111/ced.14000. Epub 2019 May 20.
3
Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.阿普米拉斯与司库奇尤单抗联合治疗一名顽固性斑块状银屑病患者
J Drugs Dermatol. 2016 May 1;15(5):648-9.
4
Psoriasis and chronic myeloid leukemia: treatment with Apremilast.银屑病与慢性髓性白血病：阿普司特治疗
Int J Dermatol. 2020 Apr;59(4):e102-e103. doi: 10.1111/ijd.14598. Epub 2019 Jul 26.
5
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).阿普米司特，一种口服磷酸二酯酶 4 抑制剂，用于治疗难治性指甲和头皮银屑病患者：两项 III 期随机对照试验（ESTEEM 1 和 ESTEEM 2）的结果。
J Am Acad Dermatol. 2016 Jan;74(1):134-42. doi: 10.1016/j.jaad.2015.09.001.
6
Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.阿普司特在中度斑块状银屑病初治患者中的疗效和安全性：UNVEIL研究的52周结果
J Drugs Dermatol. 2018 Feb 1;17(2):221-228.
7
Real-World Experience With Apremilast in Treating Psoriasis.阿普米拉斯治疗银屑病的真实世界经验。
J Cutan Med Surg. 2017 Mar/Apr;21(2):145-151. doi: 10.1177/1203475416676030. Epub 2016 Oct 23.
8
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).阿普米司特，一种口服磷酸二酯酶 4 抑制剂，治疗中重度斑块状银屑病患者的疗效和安全性：一项为期 52 周的 III 期随机对照试验（ESTEEM 2）。
Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7.
9
Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.与阿普米司特单药治疗相比，阿普米司特联合治疗1年后斑块状银屑病治疗反应的维持情况：一项多中心回顾性研究。
J Am Acad Dermatol. 2018 Nov;79(5):953-956. doi: 10.1016/j.jaad.2018.04.043. Epub 2018 May 4.
10
Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.在 LIBERATE 研究中，接受阿普司特治疗或从依那西普治疗转换的中重度斑块状银屑病患者中，阿普司特治疗 104 周的安全性和疗效。
J Eur Acad Dermatol Venereol. 2018 Mar;32(3):397-402. doi: 10.1111/jdv.14738. Epub 2018 Jan 29.

引用本文的文献

1
A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo.系统回顾了一系列病例和临床试验，调查了全身性口服或注射治疗白癜风的方法。
Skin Res Technol. 2024 Mar;30(3):e13642. doi: 10.1111/srt.13642.
2
Vitiligo: Pathogenesis and New and Emerging Treatments.白癜风：发病机制与新型及新兴治疗方法。
Int J Mol Sci. 2023 Dec 9;24(24):17306. doi: 10.3390/ijms242417306.
3
Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial.
阿普米拉斯在不稳定非节段性白癜风中作为附加治疗优于传统药物（ABCD）：一项为期12周的单中心随机对照试验。
Cureus. 2023 Apr 5;15(4):e37180. doi: 10.7759/cureus.37180. eCollection 2023 Apr.